We previously showed that the abundance of peripheral blood CD8 + CD28+ cytotoxic T lymphocytes is predictive of PFS in breast cancer, particularly in patients with HER2+ breast cancer who received anti-HER2 therapy [22]. This evidence concerns the gene ERBB2 and breast carcinoma.